by Gasper LaRosa | Dec 18, 2019 | Amendment Practice, PTAB News
By Jen Bachorik and Gasper LaRosa – In November, the PTAB Bar Association held its annual Thought Leader Summit. The Summit highlighted recent changes to PTAB practice, with a keynote address from USPTO Director Andrei Iancu. In the opening remarks, Director...
by Gasper LaRosa | Oct 21, 2019 | Other News, Stay
By Gasper LaRosa and Stephanie M. Brooker What happens when patent claims are found unpatentable in inter partes review (“IPR”) and new claims are subsequently added to that patent through ex parte reexamination? The District Court for the Northern District of...
by Gasper LaRosa | May 13, 2019 | 325(d) issues, Trial Institution
By Gasper LaRosa When exercising its broad discretion on whether to institute review, the PTAB is not limited to consideration of factors associated with the type of denial it ultimately issues. In a recent decision that the PTAB designated as precedential, the PTAB...
by Gasper LaRosa | Aug 22, 2018 | Evidentiary Issues, Motions Practice, Pharmaceutical
By: Mital B. Patel and Gasper J. LaRosa The PTAB recently granted a rare motion for additional discovery into the question of whether an unnamed party, Amneal Pharmaceuticals, LLC (“Amneal”), should have been named as a real-party-in-interest. In Kashiv LLC v. Purdue...
by Gasper LaRosa | Jul 30, 2018 | PTAB News
By: Gasper J. LaRosa Last week, Chief Judge Ruschke made the attached presentation to the International Intellectual Property Association. Chief Judge Ruschke emphasized that IPR filings appear to be leveling off and that the PTAB does not invalidate patents at a...
